STUDY ON RISK FACTORS, CLINICAL AND THERAPEUTIC PROFILE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN GOVERNMENT GENERAL HOSPITAL

  • LAKSHMI P, SUCHARITHA J Department of Pharmacy Practice, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati, Andhra Pradesh, India.
  • JAYA SINDHU M Department of Pharmacy Practice, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati, Andhra Pradesh, India.
  • CHARAN TEJA A Department of Pharmacy Practice, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati, Andhra Pradesh, India.
  • MADHURI B Department of Pharmacy Practice, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati, Andhra Pradesh, India.

Abstract

Objective: This study mainly aims to assess and evaluate risk factors, clinical and therapeutical profile in chronic obstructive pulmonary disease (COPD) patients and promote rational drug therapy; to identify the prevalence of COPD symptoms and to assess the drugs prescribed in treating COPD patients; and to evaluate patterns of diagnosing COPD in patients and determine the severity of COPD in patients using COPD assessment test (CAT).


Methods: A prospective observational study conducted in government general hospital among 220 patients for 6 months. Data were collected from patients by CAT questionnaire through interviewing each subject.


Results: The majority of the patients (36%) were in the age group of 71–80 years. Males are more prone to the COPD (91%). Most common initiation interdependence of these habits are 31–40 years and 61.8% are suffering with comorbidities. A total of 145 (65%) have social habits. About 68% of the patients are suffering from occupational exposure, 78% of the patients are suffering from old pulmonary problems.


Conclusion: Clinical pharmacist main provision is providing care to individual patients by patient counseling, regarding the rational usage of drug and also providing proper education regarding the usage of nebulizers and creating awareness to the patients.

Keywords: Chronic obstructive pulmonary disease assessment test questionnaire, Interdependence, Clinical pharmacist, Rational usage, Nebulizers

References

1. Walker R, Whittlesea C. Clinical Pharmacy and Therapeutics. 12th ed. New York: Churchill Living Stone Elsevier; 2012. p. 431-32.
2. Dipiro JT, Robert L. Pharmacotherapy a Pathological Approach. 6th ed. New York: McGraw-Hill Medical Publishing Division; 1999. p. 537-9.
3. Kasper D, Fauci A, Hauser S, Longo D, Jameson J. Harrison’s Principles of Internal Medicine. 19th ed. New York: McGraw-Hill Medical Publishing Division; 2008. p. 1632-6.
4. Innes A. Davidson’s Essentials of Medicine. 2nd ed. New York: Churchill Living Stone Elsevier; 2016. p. 265-67.
5. Jones PW, Harding G. Development and first validation of the COPD assessment test. Eur Respir J 2009;34:648-54.
6. Kristen E, Melissa R. The impact of age on outcomes in chronic obstructive pulmonary disease differs by relationship status. Natl Inst Health 2014;37:654-63.
7. Peter J. Sex differences in chronic obstructive pulmonary disease mechanisms. Am J Respir Crit Care Med 2016;193:813-4.
8. Ioanna T, Donna G. Four patients with a history of acute exacerbations of COPD: Implementing the CHEST/Canadian thoracic society guidelines for Preventing exacerbations. NPJ Prim Care Respir Med 2015;23:1-7.
9. Amar R, Pankti K. Etiology and clinical profile of COPD in non-smokers. Int J Adv Med 2018;5:1100-4.
10. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2008;33:1165-85.
11. Hammad Q, Amir S, Nicola A. Chronic obstructive pulmonary disease exacerbations latest evidence and clinical implications. Ther Adv Chron Dis 2014;5:212-27.
12. Prescott G, Graham B, Eugene B, Stephanie A. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 2018;374:1811-21.
13. Lalmolda C, Martinez N, Bare N, Teixido M, Epelde F, Monso E. Effect of a rehabilitation-based chronic disease management program targeting severe COPD exacerbations. Int J COPD 2017;12:2531-8.
14. Younmo C, Jongln L, Min C, Wonseon C, Hyoung R. Work related COPD after years of occupational exposure. Ann Occup Environ Med 2015;27:1-5.
15. Frits M, Carolyn L. Co-morbidities in patients with COPD and pulmonary rehabilitation. Series Pulm Rehabil 2014;23:131-41.
16. Victoria B, Priya V, Patrick M. Lung microbiology and exacerbations in COPD. Int J COPD 2012;7:555-69.
17. Ipsita S, Rajat D, Mehedi H, Amit W, Malabika S. Prevalence and risk factors of Chronic Obstructive Pulmonary Disease in Bangladesh. A systematic review. Cureus 2019;11:e3970.
18. Rainer B, Wuulf P. The diagnosis of chronic obstructive pulmonary disease. Cont Med Educ 2014;111:834-46.
19. Christine J. Drugs for chronic obstructive pulmonary disease. Aust Presc 2017;40:15-9.
20. Sharon R, Ravi K. Recent advances in the management of chronic obstructive pulmonary disease. F1000Res 2017;19:1-8.
Statistics
41 Views | 82 Downloads
Citations
How to Cite
P, SUCHARITHA J, L., J. SINDHU M, C. TEJA A, and M. B. “STUDY ON RISK FACTORS, CLINICAL AND THERAPEUTIC PROFILE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN GOVERNMENT GENERAL HOSPITAL”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 14, no. 3, Mar. 2021, pp. 60-65, doi:10.22159/ajpcr.2021.v14i3.40245.
Section
Original Article(s)